Advertisement

The Ubiquitin/Proteasome System in Cancer Cachexia

  • Maurizio Muscaritoli
  • Maurizio Bossola
  • Giovanni Battista Doglietto
  • Filippo Rossi Fanelli

Abstract

Cancer cachexia (CC) is probably the most debilitating and life-threatening paraneoplastic syndrome. It is characterised by weight loss, anorexia, asthaenia, loss of skeletal muscle protein, depletion of lipid stores, and severe metabolic alterations. CC syndrome is present in about 50% of cancer patients, especially those with tumours of the gastrointestinal tract and lung, and less frequently in those with haematological malignancies and other solid neoplasms, such as breast and thyroid cancer. The majority of terminally ill cancer patients experiences CC, which accounts for about 20% of cancer deaths. This figure translates into approximately 2000000 deaths per year worldwide [1].

Keywords

Gastric Cancer Gastric Cancer Patient Muscle Atrophy Cancer Cachexia Proteolytic Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Inui A (2002) Cancer anorexia-cachexia syndrome: current issues in research and management CA Cancer J Clin 52:72–91CrossRefGoogle Scholar
  2. 2.
    Muscaritoli M, Bossola M, Bellantone R, Rossi Fanelli F (2004) Therapy of muscle wasting in cancer; what is the future? Curr Opin Clin Nutr Metab Care 7:459–466PubMedCrossRefGoogle Scholar
  3. 3.
    Hasselgren PO, Fischer JE (2001) Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg 233:9–17PubMedCrossRefGoogle Scholar
  4. 4.
    Costelli P, Baccino FM (2003) Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care 6:407–412PubMedCrossRefGoogle Scholar
  5. 5.
    Langhans W (2002) Peripheral mechanisms involved with catabolism. Curr Opin Clin Nutr Metab Care 5:419–426PubMedCrossRefGoogle Scholar
  6. 6.
    Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79:13–21PubMedCrossRefGoogle Scholar
  7. 7.
    Lecker SH (2003) Ubiquitin-protein ligases in muscle wasting: multiple parallel pathways? Curr Opin Clin Nutr Metab Care 6:271–275PubMedCrossRefGoogle Scholar
  8. 8.
    Medina R, Wing SS, Haas A et al (1991) Activation of the ubiquitin-ATP-dependent proteolytic systems in skeletal muscle during fasting and denervation atrophy. Biomed Biochem Acta 50:347–356Google Scholar
  9. 9.
    Bailey GL, Wang X, England BK et al (1996) The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin proteasome pathway. J Clin Invest 97:1447–1453PubMedGoogle Scholar
  10. 10.
    Tawa NE, Odessey R, Goldberg AL (1997) Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscle. J Clin Invest 100:197–203PubMedGoogle Scholar
  11. 11.
    Price SR, Bailey JL, Wang X et al (1996) Muscle wasting in insulinopenic rats results from activation of the ATP-dependent ubiquitin proteasome proteolytic pathway by a mechanism including gene transcription. J Clin Invest 98:1703–1708PubMedGoogle Scholar
  12. 12.
    Llovera M, Garcia-Martinez C, Agell N et al (1994) Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Lett 338:311–318PubMedCrossRefGoogle Scholar
  13. 13.
    Temparis S, Asensi M, Taillandier D et al (1994) Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. Cancer Res 54:5568–5573PubMedGoogle Scholar
  14. 14.
    Costelli P, Garcia-Martinez C, Llovera M et al (1995) Muscle protein wasting in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest 95:2367–2372PubMedCrossRefGoogle Scholar
  15. 15.
    Costelli P, Bossola M, Muscaritoli M et al (2002) Anticytokine treatment prevents the increase in the activity of ATP-ubiquitinand Ca(2+)-dependent proteolytic systems in the muscle of tumourbearing rats. Cytokine 19:1–5PubMedCrossRefGoogle Scholar
  16. 16.
    Bodine SC, Latres E, Baumhueter S et al (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704–1708PubMedCrossRefGoogle Scholar
  17. 17.
    Wray CJ, Mammen JM, Hershko DD et al (2003) Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle. Int J Biochem Cell Biol 35:698–705PubMedCrossRefGoogle Scholar
  18. 18.
    Dehoux M, Van Beneden R, Fernandez-Celemin L et al (2003) Induction of MafBx and Murf ubiquitin ligase m-RNAs in rat skeletal muscles after LPS injection. FEBS Lett 544:214–217PubMedCrossRefGoogle Scholar
  19. 19.
    Jagoe RT, Lecker SH, Gomez M et al (2002) Patterns of gene expression in atrophying skeletal muscle: response to food deprivation. FASEB J 16:1697–1712PubMedCrossRefGoogle Scholar
  20. 20.
    Lecker SH, Jagoe RT, Gilbert A et al (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18:39–51PubMedCrossRefGoogle Scholar
  21. 21.
    Williams A, Sun X, Fischer JE et al (1999) The expression of genes in the ubiquitin proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 126:744–750PubMedGoogle Scholar
  22. 22.
    Bossola M, Muscaritoli M, Costelli P et al (2001) Increased muscle ubiquitin mRNA levels in gastric cancer patients Am J Physiol Regul Integr Comp Physiol 280:R1518–R1523PubMedGoogle Scholar
  23. 23.
    Bossola M, Muscaritoli M, Costelli P et al (2003) Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 237:384–389PubMedCrossRefGoogle Scholar
  24. 24.
    Jagoe RT, Redfern CP, Roberts RG et al (2002) Skeletal muscle m-RNA levels for cathepsin-B, but not components of the ubiquitin proteasome pathway are increased in patients with lung cancer referred for thoracotomy. Clin Sci 102:353–361PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Maurizio Muscaritoli
    • 1
  • Maurizio Bossola
    • 2
  • Giovanni Battista Doglietto
    • 2
  • Filippo Rossi Fanelli
    • 1
  1. 1.Department of Clinical MedicineUniversity of Rome La SapienzaRomeItaly
  2. 2.Department of SurgeryThe Catholic University of RomeRomeItaly

Personalised recommendations